Esophageal cancer comprises 2 anatomically shared but histologically different subtypes:esophageal squamous cell carcinoma(ESCC)and esophageal adenocarcinoma(EAC).Previous bulk-level genomic and clinical studies have ...Esophageal cancer comprises 2 anatomically shared but histologically different subtypes:esophageal squamous cell carcinoma(ESCC)and esophageal adenocarcinoma(EAC).Previous bulk-level genomic and clinical studies have shown that ESCC shares molecular features with head and neck squamous cell carcinoma(HNSCC)[1]and is generally more responsive to immune checkpoint blockade(ICB)therapies than EAC[2],which is similar to gastric adenocarcinoma(GAC)[1].Recent clinical trials have further demonstrated clinical benefits fromvarious ICB therapies,including combination approaches,for ESCC[3].展开更多
基金the Bio&Medical Technology Development Program of the National Research Foundation funded by the Ministry of Science and ICT(RS-2021-NR059674,RS-2022-CC125144,2022M3A9F3016364,2022R1A2C1092062,RS-2025-00553825)Brain Korea 21(BK21)FOUR program+3 种基金the Technology Innovation Program(20022947funded by the Ministry of Trade Industry&EnergyMOTIE,Korea)Yonsei Fellow Program funded by Youn Jae Lee.
文摘Esophageal cancer comprises 2 anatomically shared but histologically different subtypes:esophageal squamous cell carcinoma(ESCC)and esophageal adenocarcinoma(EAC).Previous bulk-level genomic and clinical studies have shown that ESCC shares molecular features with head and neck squamous cell carcinoma(HNSCC)[1]and is generally more responsive to immune checkpoint blockade(ICB)therapies than EAC[2],which is similar to gastric adenocarcinoma(GAC)[1].Recent clinical trials have further demonstrated clinical benefits fromvarious ICB therapies,including combination approaches,for ESCC[3].
